Epstein-barr virus, lymphoma risk and the potential role of HIV infection in IBD patients undergoing immunosuppression

Digestive Diseases

Volumn 28, Issue 3, 2010, Pages 519-524

  Weinstock, David M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Epstein Barr virus; Hepatosplenic T cell lymphoma; Inflammatory bowel disease; Lymphoma; Thiopurine

Indexed keywords

ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE;

B CELL LYMPHOMA; CANCER RISK; CONFERENCE PAPER; CROHN DISEASE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYMPOSIUM; UNITED STATES;

HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; INFLAMMATORY BOWEL DISEASES; LYMPHOMA; RISK FACTORS;

EID: 77957860139     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320411     Document Type: Conference Paper

References (19)

1. Good RA: Relations between immunity and malignancy. Proc Natl Acad Sci USA 1972; 69:1026-1032.
2. Smith MA, Irving PM, Marinaki AM, Sanderson JD: Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010, E-pub ahead of print.
3. Lakatos PL, Miheller P: Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? Cur r Drug Ta rgets 2010; 11:179-186.
4. Bewtra M, Lewis JD: Safety profile of IBD: lymphoma risks. Med Clin North Am 2010; 94: 93-113.
5. Sokol H, Beaugerie L: Inflammatory bowel disease and lymphoproliferative disorders: the dust is star ting to sett le. Gut 2009; 58: 1427-1436.
6. Lenz G, Staudt LM: Aggressive lymphomas. N Engl J Med 2010; 362:1417-1429.
7. Jaffe ES, Harris NL, Stein H, Isaacson PG: Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008; 112:4384-4399.
8. Kutok JL, Wang F: Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006; 1: 375-404.
9. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 10 0: 57-70.
10. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46:3151-3158.
11. Smedby KE, Baecklund E, Askling J: Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epi-demiol Bioma rkers Prev 2006 ; 15:2069-2077.
12. Jones JL, Loftus EV Jr: Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007; 13: 1299-1307.
13. Kandiel A, Fraser AG, Korelitz BI, Brensin-ger C, Lewis JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercapto-purine. Gut 2005; 54:1121-1125.
14. Beaugerie L, Brousse N, Bouvier AM, Co-lombel JF, Lemann M, et al: Lymphoprolif-erative disorders in patients receiving thio-purines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625.
15. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A: Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoprolifera-tive disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Tra nsplant 2006; 37: 539-546.
16. Armstrong RG, West J, Card TR: Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010; 105:1604-1609.
17. Wolfe F, Michaud K: The effect of metho-trexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433-1439.
18. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analy-sis. Clin Gastroenterol Hepatol 2009; 7:874-881.
19. Kotlyar D, Blonski W, Porter DL, Mendiza-bal M, Lin MV, et al: Hepatosplenic T cell lymphoma and inflammatory bowel disease: a rare complication after long-term thiopu-rine exposure: case report and systematic review of the literature. Digestive Disease Week, Chicago, 2009, abstr. S1133.